BioInvent International AB (publ)
BioInvent International AB (publ) (0H22.L) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for BioInvent International AB (publ) (0H22.L), featuring income statements, balance sheets, and cash flow data.
BioInvent International AB (publ) (0H22.L) Income Statement & Financial Overview
Access detailed annual and quarterly income data for BioInvent International AB (publ) 0H22.L financial performance.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $21.37M | $12.76M | $4.61M | $5.94M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $21.37M | $12.76M | $4.61M | $5.94M |
| Gross Profit Ratio | $1.00 | $1.00 | $1.00 | $1.00 |
| R&D Expenses | $129.29M | $107.47M | $138.59M | $82.38M |
| SG&A Expenses | $17.70M | $12.82M | $9.60M | $8.59M |
| Operating Expenses | $147.24M | $119.91M | $148.19M | $90.97M |
| Total Costs & Expenses | $147.24M | $119.91M | $153.07M | $95.69M |
| Interest Income | $0.00 | $9.93M | $0.00 | $11.80M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $4.88M | $4.83M | $4.88M | $4.71M |
| EBITDA | -$121.00M | -$102.31M | -$143.44M | -$85.008M |
| EBITDA Ratio | -$5.66 | -$8.02 | -$31.11 | -$14.31 |
| Operating Income | -$125.87M | -$107.15M | -$148.46M | -$89.74M |
| Operating Income Ratio | -$5.89 | -$8.39 | -$32.20 | -$15.10 |
| Other Income/Expenses (Net) | $9.04M | $9.93M | $11.04M | $11.80M |
| Income Before Tax | -$116.83M | -$97.21M | -$137.28M | -$77.92M |
| Income Before Tax Ratio | -$5.47 | -$7.62 | -$29.77 | -$13.11 |
| Income Tax Expense | $48000.00 | $28000.00 | $28000.00 | $31000.00 |
| Net Income | -$116.88M | -$97.24M | -$137.31M | -$77.95M |
| Net Income Ratio | -$5.47 | -$7.62 | -$29.78 | -$13.12 |
| EPS | -$1.78 | -$1.48 | -$2.09 | -$1.18 |
| Diluted EPS | -$1.78 | -$1.48 | -$2.09 | -$1.18 |
| Weighted Avg Shares Outstanding | $65.66M | $65.70M | $65.80M | $65.80M |
| Weighted Avg Shares Outstanding (Diluted) | $65.66M | $65.70M | $65.80M | $65.80M |
Over the last four quarters, BioInvent International AB (publ)'s revenue moved from $5.94M in Q1 2024 to $21.37M in Q4 2024. Operating income in Q4 2024 was -$125.87M, with a strong operating margin of -589%. Despite fluctuations in R&D and SG&A expenses, EBITDA for BioInvent International AB (publ) remained robust at -$121.00M, reflecting operational efficiency. Net income dropped to -$116.88M, with an EPS of -$1.78. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan